Inflamax Research, Inc. is built on a long history of scientific innovation and clinical excellence in the development of allergy, dermatology, ocular, and respiratory drugs. Under the guidance of its founders, The first EEC (Environmental Exposure Chamber) technology for allergy and asthma drug development was invented and patented under the guidance of Inflamax founders Dr. Piyush Patel and Dr. Anne Marie Salapatek. Today, the EEC technology is well respected and accepted in the field of pharmaceutical research. Inflamax continues its legacy with the most advanced EEC chambers in the world, including its mobile EEC technology (mEEC™), which makes controlled environments available anywhere on the globe in multicentre clinical trials.

Whether you have a novel compound or a generic equivalent 505(b)(2) in need of clinical pharmacology and clinical development services, we provide customers with a competitive advantage. We have participated in the clinical study of most of the mainstay drugs currently on the market for the treatment of allergy, asthma, dermatology, ocular, and respiratory treatment, many of which have achieved blockbuster status. The Inflamax Research team welcomes the opportunity to discuss your drug development needs, and to provide our scientific expertise to accelerate the development of your new treatments.

"Our clients have repeatedly told us that Inflamax differentiates itself by our scientific approach, highly knowledgeable and experienced team, ability to meet recruitment goals, project management, and ability to provide quality data outputs. We look at our clients' projects as our own. From the first moment you bring a proposal to Inflamax for consideration and feasibility, to the topline data and final reporting, your study is our top priority. We do not take on work that we cannot perform."

Dr. Anne Marie Salapatek
President & Chief Scientific Officer
Inflamax Research
Inflamax Research is a global CRO with clinical research facilities in both Canada and the US. We offer both Phase I Clinical Pharmacology and Late Phase Global Clinical Research Services. With capabilities of innovative fixed EECs and the ability to scale mEEC facilities wherever they are needed, we can meet the requirements for any clinical study at all phases of development.

Inflamax Research is a full-service CRO with unique, high-capacity single-centre capabilities and a track record of successful completion of over 800 studies. Over 2014-2015 (Q1’15) Inflamax has randomized over 2000 patients in clinical trials.

The Clinical Pharmacology Unit, with over 45,000 ft² space, comprises three independent study units including an Intensive Observation Unit. Our state-of-the-art high throughput screening facility with over 18,000 ft² supports recruitment for both our clinical pharmacology studies as well as our late phase and EEC studies.

Beyond our patented and innovative EEC technology, Inflamax scientific experts provide our clients:

• Validated scientific methods across multiple therapeutic areas
• Access to world-renown KOLs for multicentre allergy and asthma studies
• Experienced clinical trial management professionals to manage global multicentre trials and specializing in mEEC and field studies
• Adaptive Accelerated Proof-of-Concept (POC) with First-In-Human study designs are conducted under one study protocol for cost and time efficiencies
• Suite of proprietary technologies for successful patient recruitment and compliance and safety monitoring using ePRO tools, OCRUP™, and ePDAT™
• Biomarker collection in a variety of tissue and secretions and PBMC collection for cellular assays